Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455641 | 0.79 | HTR2A (0.34) | HTR2ARETHTR2CHRH1 | |
| SCHEMBL2169848 | 0.75 | HTR1A (0.39) | HTR2ARETHTR2CHRH1 | |
| SCHEMBL3389204 | 0.70 | HTR2A (0.35) | IDO1HTR2ARETHTR2CHRH1 | |
| SCHEMBL28115700 | 0.69 | IDO1 (0.34) | MEN1RECQLKMT2AIDO1HTR2A | |
| SCHEMBL4290508 | 0.68 | HTR2A (0.35) | HTR2AHTR2CHRH1 | |
| SCHEMBL4307808 | 0.68 | HTR2A (0.34) | HTR2ARETHTR2CHRH1 | |
| SCHEMBL458123 | 0.68 | HTR2A (0.34) | HTR2ARETHTR2CHRH1 | |
| SCHEMBL455932 | 0.68 | HTR2A (0.34) | HTR2ARETHTR2CHRH1 | |
| SCHEMBL458495 | 0.68 | HTR2A (0.35) | HTR2AHTR2CHRH1 | |
| SCHEMBL6521360 | 0.68 | HTR2A (0.35) | HTR2AHTR2CHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9610275-B2 | Nitrile derivatives and their pharmaceutical use and compositions | CELLCEUTIX CORPORATION (US) | 2017-04-04 | — | — | US | claimed |
| US-20120189537-A1 | NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CELLCEUTIX CORPORATION | 2012-07-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189537-A1 | NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | NOS1, NOS2, NOS3 | MEN1 2249/4885RECQL 1857/4885KMT2A 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.